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Abstract
Background: Cardiovascular disease (CVD) is a growing cause of mortality and morbidity in Tanzania, but
contextualized evidence on cost-effective medical strategies to prevent it is scarce. We aim to perform a
cost-effectiveness analysis of medical interventions for primary prevention of CVD using the World Health
Organization’s (WHO) absolute risk approach for four risk levels.
Methods: The cost-effectiveness analysis was performed from a societal perspective using two Markov decision models:
CVD risk without diabetes and CVD risk with diabetes. Primary provider and patient costs were estimated using the
ingredients approach and step-down methodologies. Epidemiological data and efficacy inputs were derived from
systematic reviews and meta-analyses. We used disability- adjusted life years (DALYs) averted as the outcome measure.
Sensitivity analyses were conducted to evaluate the robustness of the model results.
Results: For CVD low-risk patients without diabetes, medical management is not cost-effective unless willingness to pay
(WTP) is higher than US$1327 per DALY averted. For moderate-risk patients, WTP must exceed US$164 per DALY before
a combination of angiotensin converting enzyme inhibitor (ACEI) and diuretic (Diu) becomes cost-effective, while for
high-risk and very high-risk patients the thresholds are US$349 (ACEI, calcium channel blocker (CCB) and
Diu) and US$498 per DALY (ACEI, CCB, Diu and Aspirin (ASA)) respectively. For patients with CVD risk with
diabetes, a combination of sulfonylureas (Sulf), ACEI and CCB for low and moderate risk (incremental cost-
effectiveness ratio (ICER) US$608 and US$115 per DALY respectively), is the most cost-effective, while adding
biguanide (Big) to this combination yielded the most favourable ICERs of US$309 and US$350 per DALY for
high and very high risk respectively. For the latter, ASA is also part of the combination.
Conclusions: Medical preventive cardiology is very cost-effective for all risk levels except low CVD risk.
Budget impact analyses and distributional concerns should be considered further to assess governments’
ability and to whom these benefits will accrue.
Keywords: Sub-Saharan Africa, Tanzania, Primary prevention, Cardiovascular disease, Diabetes,
Cost-effectiveness analysis, Markov modelling, Societal perspective
* Correspondence: frida.ngalesoni@igs.uib.no
1Ministry of Health and Social Welfare, Dar es Salaam, Tanzania
4Department of Global Public Health and Primary Health Care, University of
Bergen, Kalfarveien 31, Post box 7804NO-5020 Bergen, Norway
Full list of author information is available at the end of the article
© 2016 Ngalesoni et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ngalesoni et al. BMC Health Services Research  (2016) 16:185 
DOI 10.1186/s12913-016-1409-3
Background
Cardiovascular disease (CVD) is a growing cause of
death and disability in sub-Saharan Africa (SSA). The
Global Burden of Disease (GBD) 2010 study showed
that, in 2000, ischemic heart disease and stroke
accounted for 1.83 and 2.47 % respectively of total
disability- adjusted life years (DALYs) lost in the region.
A decade later there had been a 15 % increase in the
percentage of total DALYs lost attributed to these condi-
tions [1]. This surge has been boosted by ongoing nutri-
tional, demographic and epidemiological transitions.
Costs ascribed to CVD are substantial; for example, in
2010, they amounted to about US$11.6 billion in the
World Health Organization’s (WHO) African region E
(AFRO E). These costs are expected to rise by 22 % by
2030 [2]. Tanzania has not been spared from this tide, as
evidence shows that the prevalence of CVD risk factors
is increasing rapidly [3–8]. Consequently, large increases
in avoidable CVD mortality and morbidity and hence
serious pressures on the already constrained health
systems are expected in the future unless preventive
measures are implemented.
Many studies on the cost-effectiveness of preventive
interventions into CVD have been conducted in high-
income countries, with significant amounts of evidence
in favour of primary prevention [9]. Evidence from indi-
vidual countries in SSA is extremely scarce [10–12].
Only a few studies focusing on interventions across
WHO and World Bank developing regions are available
[13–15], and their use of aggregated data from countries
with great diversity in terms of demographic, epidemio-
logical, socio-economic and policy contexts requires the
results to be interpreted with caution when used to
inform policy in individual countries.
Preventive cardiology in Tanzania not only receives low
priority but it is also practised in a non-comprehensive
way [16–18]. Tanzania’s previous and current preventive
guidelines [19, 20] focus unilaterally on single risk factors
but this approach has been shown to be less effective than
the absolute risk approach advocated in the WHO’s CVD
preventive guidelines and elsewhere [10, 16, 21, 22]. The
absolute risk approach gives a numerical probability of a
CVD event occurring in a given time period, e.g. one or
ten years. It combines all modifiable major risk factors for
CVD such as hypertension, cholesterol level and smoking.
The absolute risk approach also includes unmodifiable
factors like age and sex. Treatment decisions are then
based on the total risk of a CVD event [23].
There is a previous study that has explored the cost-
effectiveness of medical preventive cardiology in Tanzania
[12]. Being the first, it forms an important step for further
exploration on the subject. A new study is justifiable for
the following reasons: firstly, the previous study did not
explicitly model diabetes in its risk factor profile. Existing
literature indicates that diabetes is one of the major risk
factors for CVD [24] and tends to occur together with
other known cardiovascular risk factors [25]. Secondly,
primary cost data were not used in the estimation of inter-
vention costs. Thirdly, the current work expands from a
provider to a societal perspective by including costs to
patients of receiving treatment. Fourthly, following the
release of GBD 2010 [26], new disability weights are avail-
able and the literature on drug effectiveness has since
been updated. Finally, drugs such as simvastatin–which is
listed on the national formulary and is currently available
in Tanzania’s Medical Stores Department (MSD)–have
come off patent, and so are more likely to be affordable
and therefore policy relevant for Tanzania. In light of the
above reasons, the purpose of the present study is to per-
form a cost-effectiveness analysis of the most relevant
medical interventions for primary prevention of CVD in
Tanzania using an absolute risk approach.
Methods
Model structure
Two Markov decision models for CVD risk without dia-
betes and CVD risk with diabetes–reflecting whether or
not there is diabetes in addition to all other CVD risks–
were constructed using TreeAge Pro 2014 software for
four CVD risk cohorts. Further model details are speci-
fied in Appendix 1 to permit full replication of our
results.
Absolute risk of CVD
We constructed index cohorts representing each of the
four CVD risk levels (see Appendix 1, Table 4) guided by
the WHO’s prediction charts for AFRO E. By varying
age, gender, blood pressure, cholesterol level, smoking
and diabetes status we obtained hypothetical cohorts
representing low, medium, high and very high CVD risk
levels, respectively [22].
Description of interventions
Table 1 below presents drug interventions included in
the model.
These drugs are recommended by the WHO’s CVD
preventive guidelines [22], except for angiotensin recep-
tor blocker (ARB), which we included because its patent
recently expired. For an overview of the drug combina-
tions considered, see Appendix 2.
Input parameters
Transition probabilities
Annual risks for myocardial infarction (MI) and/or
stroke were calculated from the Framingham Heart
Study risk equations [27, 28] for the four different index
cohorts. This was motivated by the absence of such data
from the sub-Saharan region. Even though updated
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Framingham equations are available from the literature,
these could not be applied in this work since the re-
ported annual risks are combined for all CVD events
[29, 30]. Age-specific background mortality rates were
based on a Tanzanian life table [31] and were adjusted
for the mortality attributable to CVD [32]. We used age
and sex-specific case fatality rates from the WHO’s
CHOosing Interventions that are Cost-Effective
(CHOICE) study [33] (Appendix 3, Table 5).
Since stroke was classified according to severity, infor-
mation about the probabilities of “first ever stroke” and
“subsequent stroke” was necessary. These were derived
from context-specific literature and if data was unavail-
able we sought expert opinions or made assumptions
(Appendix 3, Table 6). We assumed that the probability
of subsequent strokes after the second event was
constant.
Intervention costs
Cost of CVD prevention and treatment
The direct medical costs of providing medical primary
prevention and cost to patients of receiving these ser-
vices have been estimated elsewhere [34]. The provider
cost of CVD treatment was identified and measured ac-
cording to standard protocols from Arusha urban hos-
pital using an ingredients approach. Resource valuation
followed the opportunity cost method. Unit costs were
estimated using activity-based and step-down method-
ologies. Patient cost of receiving CVD treatment was as-
sumed to be 57.5 % higher [35] than the US$123
estimated as the patient cost of receiving CVD prevent-
ive measures [34]. The costing exercise follows a “nar-
row” societal perspective, whereby costs of health care,
whether borne by the patient or the provider, are rele-
vant. Since most economic evaluations are analyzed
from the provider perspective only, a scenario analysis
was conducted to explore the impact of this viewpoint
on model recommendations. We assumed that primary
preventive care can be performed within the existing
facility setup and that upgrading of infrastructure is not
required.
Intervention effects
The intervention effects–in terms of relative risk (RR)–
of drug classes used were retrieved from systematic
reviews and meta-analyses of relevant randomized con-
trolled trials, except for oral hypoglycemics which were
based on one randomized controlled trial (RCT), see
Appendix 3, Table 6 for references. Appendix 4 presents
a summary of the comparators, RCT designs, statistical
methods used and statements on primary prevention.
The effects of interventions involving combinations of
drugs were determined multiplicatively i.e. (RR1 × RR2 ×
RRn) [36]. It was assumed that intervention effects did
not vary across the different underlying risk groups and
that it was constant across all age groups. We also as-
sumed perfect adherence to treatment.
Health outcome
We used DALYs, which combine years lived with disabil-
ity (YLDs) and years of life lost (YLLs), as our measure
of health outcomes. YLDs were based on GBD 2010 dis-
ability weights of 0.422 for acute myocardial infarction
and 0.021, 0.076 and 0.539 for mild, moderate and se-
vere stroke respectively [26]. Tanzania’s sex-specific life
expectancy in 2012 and a disability weight of 1 to reflect
the dead health state were used to calculate YLLs.
See Table 2 below for a summary of parameters and
sources.
Cost-effectiveness analysis
For the CVD risk both without and with diabetes, ex-
pected costs and outcomes were calculated for each of
the possible interventions. Base-case results are pre-
sented as incremental costs and effects and incremental
cost-effectiveness ratios (ICERs). Strategies having ICERs
below US$610, which is Tanzania’s 2012 GDP per capita
[37], (the lowest willingness to pay (WTP) value recom-
mended by the WHO [38]) were considered “very cost-
effective”. In our base case, health costs and outcomes
were non-differentially discounted at 3 % annually. A
scenario analysis was conducted to test whether and
how results vary with differential discounting. Age
weighting was not incorporated into the analysis due to
criticisms raised in the GBD 2010 study [39].
Sensitivity analyses
The rationale behind performing a sensitivity analysis is
that the uncertainty of the model parameters is mainly
due to lack of data or ambiguity regarding how the data
were collected, simplifications and assumptions made
[40, 41]. A set of one-way sensitivity analyses was
Table 1 Drug interventions for primary prevention of CVD
Drug class Acronym Drug Daily dosage
Angiotensin converting
enzyme inhibitor
ACEI Captopril 12.5 mg twice
Angiotensin receptor
blocker
ARB Losartan 50 mg once
Beta blocker BB Atenolol 50 mg once
Biguanide Big Metformin 500 mg thrice
Calcium channel blocker CCB Nifedipine 20 mg twice
Soluble aspirin ASA Aspirin 75 mg once
Statin Sta Simvastatin 40 mg once
Sulfonylureas Sulf Glibenclamide 5 mg once
Thiazide diuretics Diu Bendrofluazide 2.5 mg or 5 mg
once
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performed to evaluate the impact of single assumptions
about costs and outcomes on model results. Upper and
lower variable ranges were taken from the reported 95 %
confidence interval or calculated from the standard error
when stated. Otherwise we assumed a range of +/− 15 %
around the base case value. In the multivariate probabil-
istic uncertainty analysis, using a Monte Carlo simula-
tion, we ran the model with distributions for each
parameter rather than point estimates to determine the
probability of optimal intervention being cost-effective
against a range of cost-effectiveness thresholds [42, 43].
Value of information analysis
High-quality evidence from multiple model input
sources is not always available and decisions based on
these model recommendations are subject to costly un-
certainty. A value of information analysis allows for an
estimation of the cost of existing uncertainty, which is
determined by the function of the probability that a de-
cision will be wrong for different levels of WTP for
health and the size of the opportunity loss if the wrong
decision is made [44]. We first calculated expected value
of perfect information (EVPI) as the difference between
the expected net benefit with perfect information and
current information, and then we estimated population
EVPI assuming an annual effective hypothetical popula-




Table 3 below presents the base-case results for the two
distinct models “CVD risk” and “CVD risk with dia-
betes” for the four CVD risk levels. In the table, all dom-
inated and extendedly dominated strategies have been
excluded. The complete tables presenting cost,
incremental cost, effectiveness and incremental effective-
ness of all strategies are available from the authors by re-
quest.
For both models, simpler treatment combinations
appear most cost-effective for lower CVD risks, while
higher risks led to more complex drug combinations
being cost-effective. Generally, managing CVD risk is
more cost-effective for patients with higher risk than for
patients with lower risk, and more cost-effective for




The results suggest that providing a combination of
ACEI and Diu averts 0.41 DALYs at a cost of US$544
compared to no treatment, yielding the lowest ICER of
US$1327 per DALY averted. Adding Sta to this duother-
apy averted a further 0.08 DALYs for US$254.
Moderate risk
As for the low risk, ACEI and Diu yielded the lowest
ICER of US$164 per DALY averted. Providing this inter-
vention averts 1.02 DALYs at a cost of US$167 com-
pared to giving no medical treatment.
High risk
The lowest ICER of US$349 per DALY averted was
shown to result from providing a triple therapy of ACEI,
CCB and Diu to high-risk patients compared to no treat-
ment, whereby a cost of US$545 deterred 1.56 DALYs.
Adding Sta to this combination requires an addition of
US$607 per DALY averted.
Very high risk
Out of the three non-dominated strategies, a combin-
ation of ACEI, CCB, Diu and ASA yielded the lowest
ICER value of US$498 per DALY averted compared to
“no treatment”, by averting 2.44 DALYs for US$1216.
Adding Sta to this combination required an additional
US$189 to prevent a further 0.29 DALYs (Table 3).
CVD risk with diabetes
Low risk
Model conclusions for this risk level suggest that a com-
bination of Sulf, ACEI and CCB averts 0.85 DALYs at a
lifetime cost of US$517, resulting in an ICER of US$608
per DALY averted. Adding Big to this combination will
prevent a further 0.31 DALYs at an additional cost of
US$297, with an ICER of US$958 per DALY averted.
Table 2 Model parameters and data sources
Parameter Sources
Annual risk of MI or stroke - Table 5 Framingham Heart Study
Non-MI or non-stroke mortality
rate - Table 5
Tanzanian 2012 life table and
GHDx dataset
Fatality rate from MI and stroke - Table 5 WHO, CHOICE study
Cost of CVD prevention and
treatment - Table 6
Authors’ previous study and
primary analysis
Intervention costs and effects - Table 6 Tanzania MSD and meta-analyses
Disability weights - Table 6 Global burden of disease 2010




MI Myocardial infarction, GHDx Global Health Data Exchange, WHO World
Health Organization, CHOICE CHOosing Interventions that are Cost-Effective,
MSD Medical Stores Department
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Moderate risk
As for the low risk with diabetes, the triple therapy of one
oral hypoglycemic and two anti-hypertensives yielded the
lowest ICER of US$115 per DALY averted compared to
not providing medical management. A more complex
strategy of adding a second oral hypoglycemic required an
additional US$156 to deter a further 0.61 DALYs with an
ICER of US$256 per DALY averted.
High risk
Just over 2 DALYs are averted at a cost of US$667 by
giving two oral hypoglycemics (Big & Sulf ) and two anti-
hypertensives (ACEI & CCB), with an ICER of US$309
per DALY averted. Additional DALYs are avoided at fur-
ther cost and with more complex combinations. Adding
Sta to this combination will further prevent 0.21 DALYs
at a cost of US$192 while further addition of ARB deterred
only 0.10 DALYs at a cost of US$1030. Corresponding
ICERs are US$914 and US$10,300 per DALY averted re-
spectively compared to the preceding interventions.
Very high risk
The lowest ICER was achieved by providing Big, Sulf,
ACEI, CCB and ASA, whereby a cost of US$1182
deterred 3.38 DALYs with an ICER of US$350 per DALY
averted.
Representing uncertainty
In this sub-section, only the results for low and very
high CVD risk without and with diabetes are presented,
due to space limitations. For the results for moderate
and high risks see Appendix 5.
Deterministic sensitivity analysis
Drug treatment effects are shown to be the most uncer-
tain parameters for both low and very high CVD risk
without and with diabetes. Variables representing less
than 1 % of the total uncertainty were omitted since
changing their assumptions had a negligible effect on
the model. (Figs. 1 and 2).
Probabilistic sensitivity analysis
Figures 3 and 4 illustrate the optimal treatment paths, or
cost-effectiveness acceptability frontiers (CEAFs), for low
and very high CVD risk without and with diabetes for
varying levels of plausible WTP to avert a DALY. For
each level of WTP, the CEAFs illustrate only the optimal
Table 3 Base case results for CVD risk without and with diabetes for four risk levels. All dominated strategies have been excluded
CVD risk
Strategy Cost IC Eff IE ICER Strategy Cost IC Eff IE ICER
Low risk Moderate risk
No treatment 461 0.00 No treatment 1516 0.00
ACEI_Diu 1005 544 0.41 0.41 1327 ACEI_Diu 1683 167 1.02 1.02 164
ACEI_Diu_Sta 1259 254 0.49 0.08 3175 ACEI_Diu_Sta 1827 144 1.28 0.26 554
High risk Very high risk
No treatment 1695 0.00 No treatment 2028 0.00
ACEI_CCB_Diu 2240 545 1.56 1.56 349 ACEI_CCB_Diu_ASA 3244 1216 2.44 2.44 498
ACEI_CCB_Diu_Sta 2404 164 1.83 0.27 607 ACEI_CCB_Diu_Sta_ASA 3433 189 2.73 0.29 652
CVD risk with diabetes
Strategy Cost IC Eff IE ICER Strategy Cost IC Eff IE ICER
Low risk Moderate risk
No treatment 964 0.00 No treatment 1805 0.00
Sulf_ACEI_CCB 1481 517 0.85 0.85 608 Sulf_ACEI_CCB 1966 161 1.40 1.40 115
Big_Sulf_ACEI_CCB 1778 297 1.16 0.31 958 Big_Sulf_ACEI_CCB 2122 156 2.01 0.61 256
Big_Sulf_ACEI_CCB_Sta 2026 248 1.26 0.10 2480 Big_Sulf_ACEI_CCB_Sta 2311 189 2.21 0.20 945
High risk Very high risk
No treatment 1909 0.00 No treatment 2514 0.00
Big_Sulf_ACEI_CCB 2576 667 2.16 2.16 309 Big_Sulf_ACEI_CCB_ASA 3696 1182 3.38 3.38 350
Big_Sulf_ACEI_CCB_Sta 2768 192 2.37 0.21 914 Big_Sulf_ACEI_CCB_Sta_ASA 3893 197 3.66 0.28 704
Big_Sulf_ACEI_ARB_CCB_Sta 3798 1030 2.47 0.10 10300 Big_Sulf_ACEI_ARB_CCB_Sta_ASA 4883 990 3.79 0.13 7615
IC Incremental cost, Eff Effectiveness, IE Incremental effectiveness, ICER Incremental cost-effectiveness ratio
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Fig. 1 ICER tornado diagrams for low and very high CVD risk. a Low CVD risk. b Very high CVD risk
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Fig. 2 ICER tornado diagrams for low and very high CVD risk with diabetes. a Low CVD risk with diabetes. b Very high CVD risk with diabetes
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interventions with highest probability of being cost-
effective, while all other alternatives are excluded.
CVD prevention is not likely to be cost-effective until
WTP approaches US$1327 and US$498 per DALY
averted in patients with low and very high CVD risk
respectively. For low-risk patients, ACEI and Diu is opti-
mal for all plausible levels of WTP higher than US$1327
per DALY averted, while for very high-risk patients a
combination of ACEI, CCB, Diu and ASA is most likely
to be optimal within the WTP range of US$498–US$651
per DALY averted, after which a further addition of Sta
becomes optimal.
For patients with diabetes, WTP values of about
US$608 and US$350 for low and very high CVD risk, re-
spectively are required for CVD prevention to be cost-
effective compared to CVD risk without diabetes. For
low-risk patients, a combination of Sulf, ACEI and CCB
is optimal for WTP values between US$608 and
Fig. 3 Cost-effectiveness acceptability frontier for low and very high CVD risk
Fig. 4 Cost-effectiveness acceptability frontier for low and very high CVD risk with diabetes
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US$958, followed by Big, Sulf, ACEI and CCB for a ceil-
ing ratio exceeding US$958. For very high-risk patients,
a combination of Big, Sulf, ACEI, CCB and ASA is most
likely to be optimal in the WTP range US$350–US$704
per DALY averted, after which the further addition of
Sta becomes optimal.
The figures also illustrate that the above findings are
surrounded by substantial uncertainty, except for pa-
tients with very high CVD risk and when WTP is very
low (in which case no intervention is clearly optimal).
For example, the ACEI and Diu combination in low-risk
CVD patients without diabetes never exceeds a higher
probability of being cost-effective than around 55 %, and
consequently there is always at least a 45 % probability
of the preferred strategy being sub-optimal. For low-risk
patients with diabetes, the corresponding numbers are
75/25 % for the intervention Sulf, ACEI and CCB.
Expected value of perfect information (EVPI) analysis
Presented here are the EVPI analysis results for low and
very high CVD risk without and with diabetes. The
population EVPI–which represents the maximum
amount of funds a decision-maker, should be willing to
invest in research to eliminate all uncertainties–varied
considerably with the different values of the WTP and
risk levels (Appendix 6).
From Fig. 5 above, if Tanzanian’s WTP is US$610 then
further research is potentially cost-effective for all risk
levels except low CVD risk if the cost of proposed
research is at most US$160,000.
Scenario analyses
Societal vs provider perspective
CVD risk: There were some changes in optimal therapies
when the model was re-analyzed with patient costs ex-
cluded. For example, Diu as monotherapy became optimal
for low and moderate risk levels, with ICERs of US$723
and US$092 per DALY averted respectively, and there was
a re-emergence of BB in the non-dominated drug combi-
nations for all risk levels (Appendix 7).
CVD risk with diabetes: Model results remained largely
the same for the CVD risk with diabetes model from the
providers’ perspective. We observed the strategies Sulf,
ACEI and CCB being recommended for high-risk patients
and Sulf, ACEI, CCB and ASA for very high-risk patients,
whereas such combinations were dominated in our base
case (Appendix 7).
In both CVD risk without and with diabetes, model re-
sults from the societal perspective generally had lower
ICERs compared to those from the provider viewpoint.
Differential vs non-differential discounting
Whether or not health outcomes are to be discounted
(and at what rate) has raised a lot of debate in the field of
economic evaluation [41, 45–48]. Our base-case analysis
was performed using non-differential discounting of 3 %
for costs and health outcomes. We applied differential dis-
counting in two forms, a lower discount rate (1.5 %) and
no discount rate for health outcomes, while keeping the
discount rate for costs constant at 3 %. Lower discount
rates for health outcomes reduce the ICERs, making CVD
prevention more attractive, but model recommendations
in terms of rank ordering of the alternatives did not
change. With a lower or no discount rate for health out-
comes, more costly yet more effective strategies become
optimal for lower levels of WTP (Appendix 7).
Different index cohort definition
Our choice on index cohorts i.e. females for low risk and
males for moderate to very high risk would imply that our
main model results may not apply for males’ low-risk pa-
tients and females’ moderate to very high risks. We
Fig. 5 Population EVPI curve for low and very high CVD risk without and with diabetes
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therefore constructed and re-run the model with a new
set of index cohorts with the reverse gender and risk com-
binations (Appendix 8, Tables 11 and 12). The model con-
clusions remain robust in terms of rank ordering of the
different drug combinations, but higher willingness to pay
values are required in order to recommend interventions
to female compared to male patients (Table 3 and Ap-
pendix 8, Table 13).
Discussion
This analysis suggests that multi-drug combinations
achieve the best value for money for almost all risk levels
both in the CVD risk and CVD risk with diabetes co-
horts. If Tanzania is willing to pay up to US$610–one
Gross Domestic Product (GDP) per capita per DALY
averted, below which interventions are considered to be
very cost-effective by the WHO [38]–our model recom-
mends no medical treatment for low-risk without
diabetes patients. For a moderate risk level without dia-
betes, a combination of ACEI and Diu has an ICER that
falls below the tentative WTP threshold value. Adding
CCB to this combination was the optimal choice for
high-risk patients, while for very high-risk patients
further adding ASA is suggested. For patients with dia-
betes, a combination of Sulf, ACEI and CCB is predicted
to be optimal for low and moderate risk levels while
adding Big to this combination consistently yielded more
health for money for high and very high risk levels. For
very high-risk patients, ASA was also part of the
combination.
These conclusions are in line with the WHO’s CVD
preventive guidelines, which recommend no medical
management for low CVD risks [22]. We also observed
similar results to those demonstrated in the cost-
effectiveness analysis of primary prevention of CVD in
Australia, where they recommended Diu, CCB, ACEI
and Sta for all patients with a 5 % 5-year CVD risk. The
same conclusion cannot be drawn for our moderate-risk
patients since we assumed that triple anti-hypertensives
were not clinically relevant for this risk level.
Our results are different from those of a similar study
performed in Tanzania [12], in which their recom-
mended strategies, including combinations with BB, are
dominated in our work. Differences in study perspec-
tives, cost evidence, clinical evidence and choice of inter-
ventions analyzed meant that differences in optimal
interventions were not unlikely. For example, interven-
tions modelled in this work restricted ASA to very high-
risk patients only and included ACEI in the drug combi-
nations, which is not the case in the previous study.
Comparing our model recommendations to the WHO-
CHOICE study and a recent cost-effectiveness analysis
to combat CVD in SSA and South East Asia results, we
observed that drug combinations with Diu and BB were
dominated and that our optimal strategies included
combinations of ACEI with CCB or Diu. It is worth
noticing that in these two studies only two anti-
hypertensives, Diu and BB, were included, making com-
parability challenging [13, 49]. It suffices to say that we
observed a re-emergence of BB in the recommended
interventions in the scenario analysis from a provider
perspective. This viewpoint was followed both in the
former Tanzanian and WHO-CHOICE studies, making
our results somewhat similar if the provider perspective
was applied as base-case.
Our literature search revealed no studies analyzing op-
tions to prevent CVD in patients with diabetes. So we
compared our results for this cohort with the WHO’s
CVD guidelines, which recommend metformin (biguan-
ide) as the oral hypoglycemic drug of choice. We find
that glibenclamide (sulfonylureas) is optimal for low and
moderate-risk patients, while adding metformin to glib-
enclamide is likely to be optimal for higher risk levels.
Our decision rule is based on the WHO’s proposed
cost-effectiveness threshold of one times GDP per capita
for Tanzania. This is because of the lack of a ceiling ratio
set by Tanzania’s decision-makers. However, the use of
WHO’s recommended cost-effectiveness benchmarks of
one and three times GDP per capita [38] has received
some criticisms. The basis of this threshold is unclear; as
such, it is not known whether it infers values based on
previous decisions or is set to optimally determine or ex-
haust the healthcare budgets of some representative coun-
tries [50]. Its use tends to make “almost” all healthcare
interventions and programmes seem cost-effective and
does not reflect the reality of resource constraints, hence
challenging countries to introduce virtually any cost-
effective interventions, which may end up with very low
coverage and hence exacerbate healthcare inequalities
[51]. Tanzania should preferably determine its own ceiling
ratio by tailoring its recommendations to its own budget-
ary constraints, epidemiological and demographic profile,
existing health infrastructure and other health-system
considerations. Several approaches have been proposed to
define the value of willingness to pay ceilings [50, 52, 53].
Most cost-effectiveness guidelines recommend a pro-
vider perspective in order to inform decisions about effi-
cient use of healthcare resources [54]. The societal
perspective has also been proposed in some guidelines
because it is more consistent with welfare economics.
Whether it is possible to fully adopt a societal perspec-
tive in cost-effectiveness analysis has been discussed
[54–56]. We do not claim to have adopted a broad soci-
etal perspective, but a rather “narrow” one since we only
expanded the providers’ perspective by including patient
costs. The ICER results were more favourable from the
societal than the provider perspective, which implies that
ignoring patient costs could lead to sub-optimal
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resource allocation. It is equally true that including all
relevant societal costs and benefits could significantly
alter what we, in this work, consider to be very cost-
effective.
Assuming the WTP value of US$610 and a proposed
cost of research of about US$250,000, there will be value
for further information for very high CVD risk without
diabetes and low CVD risk with diabetes since their
population EVPI exceeds the estimates of the proposed
research. Current information regarding low CVD risk
without diabetes is deem sufficient given its microscopic
population EVPI value. Further exploration is required
to determine what type of additional evidence would
be most valuable and the most efficient research
design [44]. In practice, though, the value of research
will be lower since some uncertainty will always
remain.
Strengths and limitations
We adopt a “narrow” societal perspective in this study
by taking into account patient costs. This viewpoint cap-
tures societal benefits that are not captured from more
restricted viewpoints [56]. This work also analyzed inter-
ventions for all CVD risk levels, both without and with
diabetes; although extensive, this permits comparisons
within levels and between the two models for a better
understanding of what does (or does not) work for each
level of CVD risk.
These results should also be considered in light of
model limitations. Firstly, the risk of myocardial infarc-
tion and stroke and drug treatment effects are based on
data from trials carried out in developed countries, since
good Tanzanian or regional data were unavailable. Sec-
ondly, effectiveness data for two drug classes (biguanide
and glibenclamide) were extracted from one trial only,
but again this was motivated by lack of data. Thirdly, we
did not synthesize the evidence structure as we should
have. Ideally, since most of our efficacy data were from
trials with placebo as a comparator, indirect treatment
comparisons (ITC) should have been performed and, in
the very few instances where data was from other com-
parators, mixed treatment comparisons (MTC) should
have been made. This weakness in inference concerning
the relative efficacy of all treatments considered could
possibly bias our results. However, these complex expan-
sions of standard meta-analysis evidence are only as
good as the trials included in them. Given the lack of a
strong evidence base in our setting and since choices in
healthcare resource allocation have to be made, we feel
that our model results could, at this point, sufficiently
inform these decisions [57]. Fourthly, we did not ac-
count for non-adherence to treatment in our model for
reasons of simplification and lack of data, and our model
may therefore not reflect real adherence in long-term
treatment. Non-adherence would likely reduce the effi-
cacy of the pharmacological drugs modelled, which
would pull result in the direction of less favourable ICER
estimates. On the other side, nonadherence represents
cost savings, which would pull in the opposite direction.
The overall effect on the estimates is an empirical ques-
tion, but our intuition is that the former effect would
weight more heavily, and that low adherence potentially
would make ICERs somewhat less attractive. Lastly, we
should expect the effectiveness values of our interven-
tions to be lower in practice than the ones used in this
work since the efficacy data are extracted from a “con-
trolled” trial setting.
Conclusion
Multiple drug combinations as a means of preventive
cardiology yield ICERs lower than the proposed ceiling
ratio of one GDP per capita for all risk levels except low
CVD risk, which renders them very cost-effective. How-
ever, our model conclusions are surrounded by high
uncertainty regarding both whether or not to treat and
optimal treatment choice. The results of the value of
information analysis suggest that it is potentially cost-
effective to perform research to reduce uncertainties
around model recommendations even at the lower WTP
of US$610. Decision-makers could therefore simultan-
eously adopt the model recommendations and consider
further research, since the adoption decision is revers-
ible. The fact that interventions are cost-effective given
current information does not automatically mean that
they should be recommended for implementation, since
health systems usually have other recourse competing
“very cost-effective” interventions that have not been
fully implemented. There are also other objectives be-
sides maximizing population health outcomes. Budget
impact analysis and distributional concerns should be
considered, for example, to assess governments’ ability
and to whom these benefits will accrue.
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The CVD prevention model is a probabilistic
Markov model that provides information on health
and healthcare costs over the lifetime of a hypothet-
ical Tanzanian population (or population sub-groups).
Two Markov decision models for CVD risk without
diabetes and CVD risk with diabetes were constructed
using TreeAge Pro 2014 software (Figure 6) for four
CVD risk cohorts. Modelling them separately was ne-
cessary since CVD have different risk and treatment
profiles depending on whether or not the patient is
diabetic.
Six mutually exclusive health states were considered:
“no history of CVD” (i.e. no previous myocardial infarc-
tion or stroke), “history of myocardial infarction”, and
“history of stroke”. Finally, “death” was modelled as an
absorbing state. Stroke was modelled in three different
health states based on severity: “mild”, “moderate” or
“severe”, in order to be consistent with disability weights
reported in the GBD 2010 [26].
A cohort of healthy individuals with “no history of
CVD” first enters the model at the age of 40 years. The
cohort then transits between the different health states
according to age-specific risks for each type of clinical
event and depending on the risk reduction from the al-
ternative preventive drugs. Each type of health state
Fig. 6 Model structure - CVD primary prevention
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incurs costs and changes in health outcomes which are
re-calculated after every annual cycle. A 60-year time
horizon was considered to reflect the chronic nature of
CVD.
In each model, “no treatment” was the baseline
strategy and was compared with different medical in-
terventions (singly or in combination) for primary
prevention of CVD. The inclusion of “no treatment”
as a comparator was important to allow for low-risk
groups for whom treatment is not likely to be cost-ef-
fective. In order to explore the effects of the interven-
tions in different populations, four distinct sub-
models were created to represent four CVD risk
levels: low risk, moderate risk, high risk and very high
risk with a 10-year risk of CVD event of < 10 %, 10-
19 %, 20-30 % and >30 % respectively.
Appendix 2
Figure 7 presents the strategies analyzed in the
CVD model diagrammatically. For low and moderate
CVD risk, the strategies modelled are represented by
“Package LM”, which consists of individual anti-hy-
pertensives ACEI, ARB, BB, CCB and Diu in mono
and duotherapy as shown by the inner circle in the
diagram under the label “Low and moderate risk”.
Package LM is then combined with statin, e.g. ACEI
+ statin, ACEI + ARB + statin etc. represented by the
“statin circle” embedded in the inner circle. Third,
statin alone is also analyzed for this risk level and
lastly “no treatment” option is also included, making
a total of 32 interventions modelled.
Interventions modelled for high risk consist of: (i) All
the interventions under Package LM, i.e. the 15 anti-hy-
pertensives in mono and duo therapy, (ii) “Package H”
which is anti-hypertensives in triple therapy - a total of
10 options, (iii) Package LM and Package H combined
with statin, e.g. ACEI + statin, ACEI + ARB + statin,
ACEI + ARB + BB + statin. (iv) No treatment option.
Fifty-one (51) interventions were analyzed for this risk
level.
Lastly, strategies considered for very high-risk patients
are interventions analyzed under Package LM and Pack-
age H but now combined with soluble aspirin, e.g. ACEI
+ ASA, ACEI + ARB + ASA, ACEI + ARB + BB + ASA,
represented by the inner circle with “ASA circle” embed-
ded within it in the diagram under “Very high risk”.
These interventions are marked “Package VH”. All
these combinations are then combined with statin, e.g.
ACEI +ASA+ statin, ACEI +ARB+ASA+ statin, ACEI +
ARB +BB+ASA+ statin. With the no treatment option,
the strategies made up a total of 51 interventions modelled.
The same approach can be used to interpret these
diagrams, indicating the interventions analyzed for
the four levels of CVD risk with diabetes. A total of
43 interventions were modelled for low and moderate
CVD with diabetes risk levels while the number was
49 options for high and very high CVD with diabetes
risk levels.
As depicted in Figure 8, drug combinations considered
in the analysis consisted of up to two antihypertensives
together with other drug classes for low and moderate
risks. For these levels we assumed that combinations of
three anti-hypertensives are clinically irrelevant. All
other possible combinations without and with soluble
aspirin were modelled for high and very high risks re-
spectively. Soluble aspirin was included only for very
high-risk patients, where it has been shown to be more
beneficial than harmful [22].
Table 4 Base case index cohort’s characteristics according to CVD risk levels
Index cohort Low risk Moderate risk High risk Very high risk
Without diabetes
Total cholesterol 4 mmol >8 mmol >8 mmol >8 mmol
Systolic blood pressure 120-139 mmHg 140-159 mmHg 160-179 mmHg 160-179 mmHg
Smoking No No No Yes
Sex Female Male Male Male
With diabetes
Total cholesterol 4 mmol 7 mmol1 6 mmol2 >8 mmol
Systolic blood pressure 120-139 mmHg 140-159 mmHg 160-179 mmHg 160-179 mmHg
Smoking No No No Yes
Sex Female Male Male Male
Age groups were: 40–49, 50–59, 60–69, 70–79, 80–89 and 90–99 (Appendix 3 Table 5); 1 6 mmol and 5 mmol used for age group 60–69 and age groups >
70 years respectively; 2 5 mmol used for age groups > 70 years
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Fig. 7 Interventions analysed for each CVD risk level
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Fig. 8 Interventions analysed for each CVD with diabetes risk level
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Appendix 3
Table 5 Annual risk of acute myocardial infarction and stroke, background mortality and case fatality rates
No previous history of acute myocardial infarction (AMI) or stroke
CVD risk
Acute myocardial infarction Stroke
Age Low Moderate High Very high Low Moderate High Very high
40-49 0.0020 0.0130 0.0160 0.0230 0.0020 0.0050 0.0060 0.0100
50-59 0.0040 0.0190 0.0230 0.0310 0.0020 0.0050 0.0070 0.0110
60-69 0.0060 0.0290 0.0310 0.0400 0.0040 0.0070 0.0100 0.0150
70-79 0.0060 0.0360 0.0380 0.0440 0.0060 0.0110 0.0150 0.0220
80-89 0.0070 0.0390 0.0430 0.0520 0.0110 0.0170 0.0220 0.0330
90-99 0.0080 0.0440 0.0480 0.0570 0.0190 0.0190 0.0360 0.0460
CVD risk with diabetes
40-49 0.0050 0.0140 0.0140 0.0290 0.0030 0.0060 0.0080 0.0130
50-59 0.0080 0.0210 0.0210 0.0380 0.0040 0.0070 0.0100 0.0150
60-69 0.0120 0.0270 0.0290 0.0440 0.0060 0.0100 0.0130 0.0200
70-79 0.0130 0.0290 0.0310 0.0460 0.0110 0.0150 0.0200 0.0290
80-89 0.0140 0.0350 0.0370 0.0570 0.0190 0.0220 0.0290 0.0420
90-99 0.0160 0.0390 0.0430 0.0620 0.0320 0.0290 0.0350 0.0630
With previous history of AMI or stroke
CVD risk
Acute myocardial infarction Stroke
Age Low Moderate High Very high Low Moderate High Very high
40-49 0.0021 0.0143 0.0184 0.0276 0.0023 0.0059 0.0072 0.0133
50-59 0.0042 0.0209 0.0265 0.0372 0.0023 0.0059 0.0084 0.0146
60-69 0.0063 0.0319 0.0357 0.0480 0.0045 0.0082 0.0120 0.0200
70-79 0.0063 0.0396 0.0437 0.0528 0.0068 0.0129 0.0180 0.0293
80-89 0.0074 0.0429 0.0495 0.0624 0.0124 0.0199 0.0264 0.0439
90-99 0.0084 0.0484 0.0552 0.0684 0.0215 0.0222 0.0432 0.0612
CVD risk with diabetes
40-49 0.0053 0.0154 0.0161 0.0348 0.0034 0.0070 0.0096 0.0173
50-59 0.0084 0.0231 0.0242 0.0456 0.0045 0.0082 0.0120 0.0200
60-69 0.0126 0.0297 0.0334 0.0528 0.0068 0.0117 0.0156 0.0266
70-79 0.0137 0.0319 0.0357 0.0552 0.0124 0.0176 0.0240 0.0386
80-89 0.0147 0.0385 0.0426 0.0684 0.0215 0.0257 0.0348 0.0559
90-99 0.0168 0.0429 0.0495 0.0744 0.0362 0.0339 0.0420 0.0838
Case Fatality rate
Acute myocardial infarction Stroke Background mortality
Age Males Females Males Females Age
40-49 0.3040 0.4070 0.3470 0.3520 40-49 0.0112
50-59 0.3110 0.4120 0.2480 0.1980 50-59 0.0120
60-69 0.3360 0.4300 0.2830 0.2520 60-69 0.0225
70-79 0.3670 0.4510 0.4200 0.4120 70-79 0.0467
80-89 0.4090 0.4840 0.6420 0.6650 80-89 0.1006
90-99 0.4510 0.5170 0.7920 0.8150 90-99 0.1458
Ngalesoni et al. BMC Health Services Research  (2016) 16:185 Page 16 of 29
Table 6 Intervention effects, costs, disability weights and other transition probabilities
Parameter Model input§ (95 % CI) Source
a. Intervention effects and costs
Angiotensin converting enzyme inhibitor
RR1 MI2 0.81(0.70 - 0.94) [58]
Stroke 0.65(0.52 - 0.82)
Cost3 14.10 [59]
Angiotensin receptor blocker
RR MI 0.94 (0.85 - 1.03) [60]
Stroke 0.91(0.85 - 0.98)
Cost 64.83 [59]
Beta-blocker
RR MI 0.90 (0.78 - 1.03) [58]
Stroke 0.83 (0.72 - 0.97)
Cost 6.82 [59]
Biguanide
RR MI 0.67 (0.51 - 0.89) [61]
Stroke 0.80 (0.50 - 1.27)
Cost 21.15 [59]
Calcium channel blocker
RR MI 0.85 (0.78 - 0.92) [62]
Stroke 0.66 (0.58 - 0.75)
Cost 13.19 [59]
Soluble Aspirin
RR MI 0.77 (0.69 - 0.86) [63]
Stroke 0.95 (0.85 - 1.06)
Cost 14.79 [59]
Statin
RR MI 0.86 (0.82 - 0.90) [64]
Stroke 0.90 (0.85 - 0.95)
Cost 15.92 [59]
Sulfonylureas
RR MI 0.85 (0.74 - 0.97) [61]
Stroke 0.91 (0.73 - 1.13)
Cost 6.37 [59]
Thiazide diuretics
RR MI 0.84 (0.75 - 0.95) [58]
Stroke 0.63 (0.57 - 0.71)
Cost 1.18 [59]
b. Costs
Cost of CVD4 prevention
Patient cost per OPD5 visit 15.1 [34]¶
Provider cost per OPD visit 7.15
Provider cost per lab test 4.07
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Table 6 Intervention effects, costs, disability weights and other transition probabilities (Continued)
Cost of CVD treatment
Patient cost per CVD treatment 194 [35]
MI Mild stroke Mod.6 stroke Sev.7 stroke
CVD risk - first year 310 271 512 570 Estimation
CVD risk - subsequent years 260 67 76 313
CVD risk with diabetes - first year 358 319 560 594
CVD risk with diabetes - subsequent years 308 115 124 361
c. Disability weights8
Acute MI 0.42 (0.28 - 0.57) [26]
Mild stroke 0.02 (0.01 - 0.04)
Moderate stroke 0.08 (0.05 - 0.11)
Severe stroke 0.54 (0.36 - 0.71)
d. Other probabilities
In the event of a first ever stroke,
what is the probability of a:
mild stroke for a CVD risk 0.19 [65, 66]
moderate for a CVD risk 0.44 Extrapolation
severe for a CVD risk 0.27 and
mild stroke for a CVD risk with diabetes 0.15 assumptions
moderate for a CVD risk with diabetes 0.35
severe for a CVD risk with diabetes 0.50
In the event of a subsequent stroke,




1RR - Relative risk with beta distribution fitted; 2MI - Myocardial in arction; 3Cost - All costs are in 2012 US$ and were fitted with a gamma distribution; 4CVD -
Cardiovascular disease; 5OPD - Out-patient department; 6Mod. - Moderate; 7Sev. - Severe; 8Beta distribution was fitted disability weights and other probabilities;
§All model parameters were varied at ± 15 % unless stated; ¶ provider cost per OPD visit is the average cost per visit for the four facilities costed, provider cost
per lab test available from Table 5, Patient cost per OPD visit was derived from annual patient cost divided by average number of clinic visits [34].
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Appendix 4
Table 7 Summary of meta-analyses and individual trials from which intervention effects were extracted
Drug class Trials Drug names Comparator Type Blinded Statistical method Notes
ACEI 3 Ramipril, Deserpidine, Placebo MA Double* RR, M-H, fixed, Chi2 72 % PP
Perindopril, Captopril
ARB 17 Cardisartan, Valsartan, Placebo MA NR~ RR, random, fixed, I2 NR
Irbesartan, Telmisartan,
Lorsartan
ASA 6 Soluble aspirin Placebo1 MA Blindedƪ Rate ratio, NS, X2 PP trials only
BB 5 Propanolol, Atenolol Placebo MA Double§ RR, M-H, fixed, Chi2 72 % PP
Big 1 Metformin Conventional therapy RCTs No NA NA
CCB 22▪ NR Placebo MA Double† RR, M-H, fixed, Chi2 NR
Diu 19 Indapamide, CHTD,
Chlorothiazide,
Placebo MA Double¶ RR, M-H, fixed, Chi2 72 % PP
HCTZ, Bendrofluazide, T
richloromethiazide




Sulf 1 Sulfonylureas-insulin Conventional therapy RCTs No NA NA
ACEI - Angiotensin Converting Enzyme Inhibitor, ARB - Angiotensin Receptor Blocker, Asp - Soluble Aspirin, BB - Beta Blocker, Big - Biguanide, CCB - Calcium
Channel Blocker, Diu - Diuretic, Sta - Statins, Sulf - Sulfonylureas, CHTD - Chlorothalidone, HCTZ - Hydrochlorothiazide, UC - usual care, MA - Meta analyses, RCTs -
Randomized Controlled Trials, NR - Not reported, RR - Relative risk, M-H - Mantel Haenszel, OR - Odds ratio, PP - Primary prevention, SP - Secondary prevention,
NA - Not applicable, 22▪ - These are trials which reported MI events; 9 reported stroke events, Double* - two trials were open label, NR ~ − Even though blinding
was not reported it was considered in trial quality, Placebo1 - Two trials compared aspirin with no comparator and open-label vitamin E, Blindedƪ - Two trials
were open trials, Double§ - One trial was single blinded and one open trial, Double† - One trial was not blinded, Double¶ - Four trials were single blinded and
three trials were open, Double‡ - Blinding status was not reported for one trial. For those drug classes which were not compared with placebo, we assume that
comparability between different drug classes remains valid since a non- pharmacological agent was used. Ideally a mixed treatment comparison analysis should
have been performed with all the drug classes whose comparator was not a placebo
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Appendix 5
Fig. 9 ICER tornado diagrams for moderate and high CVD risk. a Moderate CVD risk. b High CVD risk
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Fig. 10 ICER tornado diagrams for moderate and high CVD risk with diabetes. a Moderate CVD risk with diabetes. b High CVD risk with diabetes
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Fig. 11 Cost effectiveness acceptability frontier for moderate and high CVD risk
Fig. 12 Cost effectiveness acceptability frontier for moderate and high CVD risk with diabetes
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Appendix 6
Table 8 Expected Value of Perfect Information (EVPI) and population EVPI1 according to CVD risk levels
Low risk Moderate risk High risk Very high risk
WTP value ($) EVPI pop EVPI EVPI pop EVPI EVPI pop EVPI EVPI pop EVPI
CVD risk
305 0.0 0.0 44 382196 43 379456 0.2 1413
610 0.0 0.0 58 509069 62 545863 51 450067
915 01 7683 57 498410 47 412599 37 320778
1220 25 223152 67 590630 48 424051 36 319205
1525 38 331920 80 700692 52 457304 39 342096
1830 35 305884 93 820013 56 496261 42 370022
CVD risk with diabetes
305 0.2 2027 55 482549 93 816305 38 330960
610 38 338058 14 123327 16 142351 18 160405
915 68 594776 21 182611 26 226298 08 71701
1220 37 324309 09 80525 07 63077 01 11007
1525 19 166059 03 22511 02 13393 0.2 2188
1830 13 115602 01 6711 0.3 2937 0.1 893
1 Population EVPI for 1000 patients, 10 years, 3 % discount rate; pop - population; WTP - Willingness to pay
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Appendix 7
Table 9 Provider perspective results for four CVD risk levels without and with diabetes. All dominated strategies have been
excluded
CVD risk
Strategy Cost IC Eff IE ICER Strategy Cost IC Eff IE ICER
Low risk Moderate risk
No treatment 250 0.00 No treatment 855 0.00
Diu 409 159 0.22 0.22 723 Diu 903 048 0.52 0.52 092
BB Diu 508 099 0.32 0.10 990 BB Diu 945 042 0.77 0.25 168
ACEI Diu 617 109 0.41 0.09 1211 ACEI Diu 1000 055 1.02 0.25 220
ACEI Diu Sta 884 267 0.49 0.08 3338 ACEI Diu Sta 1188 188 1.28 0.26 723
High risk Very high risk
No treatment 955 0.00 No treatment 1161 0.00
ACEI BB Diu 1278 323 1.40 1.40 231 ACEI BB Diu ASA 1831 670 2.27 2.27 295
ACEI CCB Diu 1347 069 1.56 0.16 431 ACEI CCB Diu ASA 1905 074 2.47 0.20 370
ACEI CCB Diu Sta 1548 201 1.83 0.27 744 ACEI CCB Diu Sta ASA 2118 213 2.76 0.29 735
CVD risk with diabetes
Strategy Cost IC Eff IE ICER Strategy Cost IC Eff IE ICER
Low risk Moderate risk
No treatment 548 0.00 No treatment 1099 0.00
Sulf ACEI CCB 1027 479 0.85 0.85 564 Sulf ACEI CCB 1304 205 1.40 1.40 146
Big Sulf ACEI CCB 1371 344 1.16 0.31 1110 Big Sulf ACEI CCB 1561 257 2.01 0.61 421
Big Sulf ACEI CCB Sta 1633 262 1.26 0.10 2620 Big Sulf ACEI CCB Sta 1783 222 2.21 0.20 1110
High risk Very high risk
No treatment 1160 0.00 No treatment 1516 0.00
Sulf ACEI CCB 1479 319 1.52 1.52 210 Sulf ACEI CCB ASA 2067 551 2.54 2.54 217
Big Sulf ACEI CCB 1757 278 2.16 0.64 434 Big Sulf ACEI CCB 2365 298 3.36 0.82 363
Big Sulf ACEI CCB Sta 1978 221 2.37 0.21 1052 Big Sulf ACEI CCB Sta ASA 2584 219 3.64 0.28 782
Big Sulf ACEI ARB CCB Sta 3022 1044 2.47 0.10 10440 Big Sulf ACEI ARB CCB Sta ASA 3585 1001 3.77 0.13 7700
IC - Incremental cost; Eff - Effectiveness; IE - Incremental effectiveness; ICER - Incremental cost-effectiveness ratio
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Table 10 Differential discounting results for CVD risk without and with diabetes for four risk levels. All dominated strategies have
been excluded
Base case Lower DR No DR Base case Lower DR No DR
Strategy oDR - 3 % oDR - 1.5 % oDR - 0 % Strategy oDR - 3 % oDR - 1.5 % oDR - 0 %
CVD risk
Low risk ICER Moderate risk ICER
No treatment No treatment
ACEI_Diu 1327 907 585 ACEI_Diu 164 118 082
ACEI_Diu_Sta 3175 2121 1497 ACEI_Diu_Sta 554 379 262
High risk Very high risk
No treatment No treatment
ACEI_CCB_Diu 349 252 176 ACEI_CCB_Diu_ASA 498 364 258
ACEI_CCB_Diu_Sta 607 432 293 ACEI_CCB_Diu_Sta_ASA 652 461 315
CVD risk with diabetes
Low risk Moderate risk
No treatment No treatment
Sulf_ACEI_CCB 608 465 311 Sulf_ACEI_CCB 115 083 058
Big_Sulf_ACEI_CCB 958 645 430 Big_Sulf_ACEI_CCB 256 179 123
Big_Sulf_ACEI_CCB_Sta 2480 1769 1126 Big_Sulf_ACEI_CCB_Sta 945 675 450
High risk Very high risk
No treatment No treatment
Big_Sulf_ACEI_CCB 309 222 154 Big_Sulf_ACEI_CCB_ASA 350 258 184
Big_Sulf_ACEI_CCB_Sta 914 640 436 Big Sulf ACEI CCB Sta ASA 704 505 346
Big Sulf ACEI ARB CCB Sta 10300 7357 4905 Big Sulf ACEI ARB CCB Sta ASA 7615 4950 3536
DR - Discount rate; ICER - Incremental cost-effectiveness ratio
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Appendix 8
Table 11 Index cohort’s characteristics according to CVD risk levels*
Index cohort Low risk Moderate risk High risk Very high risk
Without diabetes
Total cholesterol 4 mmol >8 mmol1 >8 mmol >8 mmol
Systolic blood pressure 120-139 mmHg 140-159 mmHg2 160-179 mmHg >180 mmHg
Smoking No No No Yes
Sex Male Female Female Female
With diabetes
Total cholesterol 4 mmol 6 mmol 7 mmol4 >8 mmol
Systolic blood pressure 120-139 mmHg 140-159 mmHg3 160-179 mmHg 160-179 mmHg
Smoking No No No Yes
Sex Male Female Female Female
*These are the index characteristics of the genders not represented in tie main results. Age groups were: 40–49, 50–59, 60–69, 70–79, 80–89 and 90–99 (Table 12);
17 mmol used for age group 40–49; 2160-179 mmHg applied to age group 40–49; 3160-179 mmHg used for age groups 40–59; 46 mmol used for age groups > 60 years
Table 12 Annual risk of acute myocardial infarction and stroke for low CVD risk males and moderate to very high CVD risk females
No previous history of acute myocardial infarction (AMI) or stroke
CVD risk
Acute myocardial infarction Stroke
Age Low Moderate High Very high Low Moderate High Very high
40-49 0.0040 0.0080 0.0100 0.0180 0.0040 0.0030 0.0030 0.0080
50-59 0.0060 0.0140 0.0160 0.0250 0.0040 0.0030 0.0040 0.0090
60-69 0.0100 0.0180 0.0210 0.0310 0.0050 0.0050 0.0060 0.0160
70-79 0.0140 0.0190 0.0230 0.0330 0.0080 0.0090 0.0110 0.0270
80-89 0.0190 0.0210 0.0250 0.0360 0.0130 0.0160 0.0190 0.0430
90-99 0.0230 0.0230 0.0270 0.0380 0.0150 0.0270 0.0320 0.0640
CVD risk with diabetes
40-49 0.0060 0.0130 0.0160 0.0270 0.0050 0.0050 0.0050 0.0090
50-59 0.0090 0.0190 0.0230 0.0360 0.0050 0.0060 0.0060 0.0110
60-69 0.0140 0.0210 0.0250 0.0420 0.0070 0.0090 0.0110 0.0190
70-79 0.0190 0.0230 0.0270 0.0440 0.0110 0.0160 0.0190 0.0320
80-89 0.0240 0.0250 0.0290 0.0510 0.0170 0.0270 0.0320 0.0500
90-99 0.0290 0.0270 0.0310 0.0560 0.0190 0.0430 0.0500 0.0710
With previous history of AMI or stroke
CVD risk
Acute myocardial infarction Stroke
Age Low Moderate High Very high Low Moderate High Very high
40-49 0.0042 0.0088 0.0115 0.0216 0.0045 0.0035 0.0036 0.0106
50-59 0.0063 0.0154 0.0184 0.0300 0.0045 0.0035 0.0048 0.0120
60-69 0.0105 0.0198 0.0242 0.0372 0.0057 0.0059 0.0072 0.0213
70-79 0.0147 0.0209 0.0265 0.0396 0.0090 0.0105 0.0132 0.0359
80-89 0.0200 0.0231 0.0288 0.0432 0.0147 0.0187 0.0228 0.0572
90-99 0.0242 0.0253 0.0311 0.0456 0.0170 0.0316 0.0384 0.0851
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Table 12 Annual risk of acute myocardial infarction and stroke for low CVD risk males and moderate to very high CVD risk females
(Continued)
CVD risk with diabetes
40-49 0.0063 0.0143 0.0184 0.0324 0.0057 0.0059 0.0060 0.0120
50-59 0.0095 0.0209 0.0265 0.0432 0.0057 0.0070 0.0072 0.0146
60-69 0.0147 0.0231 0.0288 0.0504 0.0079 0.0105 0.0132 0.0253
70-79 0.0200 0.0253 0.0311 0.0528 0.0124 0.0187 0.0228 0.0426
80-89 0.0252 0.0275 0.0334 0.0612 0.0192 0.0316 0.0384 0.0665
90-99 0.0305 0.0297 0.0357 0.0672 0.0215 0.0503 0.0600 0.0944
Table 13 Cost-effectiveness results for low CVD risk males and moderate to very high CVD risk females without and with diabetes.
All dominated strategies have been excluded
CVD risk
Strategy Cost IC Eff IE ICER Strategy Cost IC Eff IE ICER
Low risk Moderate risk
No treatment 799 0.00 No treatment 991 0.00
ACEI Diu 1202 403 0.61 0.61 661 ACEI Diu 1330 339 0.82 0.82 413
ACEI Diu Sta 1424 222 0.74 0.13 1708 ACEI Diu Sta 1525 195 1.02 0.20 975
High risk Very high risk
No treatment 1112 0.00 No treatment 1591 0.00
ACEI CCB Diu 1941 829 1.22 1.22 680 ACEI CCB Diu ASA 3059 1468 2.30 2.30 638
ACEI CCB Diu Sta 2152 211 1.43 0.21 1005 ACEI CCB Diu Sta ASA 3277 218 2.56 0.26 838
CVD risk with diabetes
Strategy Cost IC Eff IE ICER Strategy Cost IC Eff IE ICER
Low risk Moderate risk
No treatment 1175 0.00 No treatment 1467 0.00
Sulf ACEI CCB 1619 444 0.95 0.95 467 Sulf ACEI CCB 1756 289 1.36 1.36 213
Big Sulf ACEI CCB 1878 259 1.30 0.35 740 Big Sulf ACEI CCB 1971 215 1.94 0.58 371
Big Sulf ACEI CCB Sta 2110 232 1.42 0.12 1933 Big Sulf ACEI CCB Sta 2182 211 2.13 0.19 1111
High risk Very high risk
No treatment 1602 0.00 No treatment 2060 0.00
Big Sulf ACEI CCB 2446 844 2.17 2.17 389 Big Sulf ACEI CCB ASA 3539 1479 3.37 3.37 439
Big Sulf ACEI CCB Sta 2654 208 2.38 0.21 991 Big Sulf ACEI CCB Sta ASA 3757 218 3.64 0.27 807
Big Sulf ACEI ARB CCB Sta 3700 1046 2.48 0.10 10460 Big Sulf ACEI ARB CCB Sta ASA 4770 1013 3.77 0.13 7792
IC - Incremental cost; Eff - Effectiveness; IE - Incremental effectiveness; ICER - Incremental cost-effectiveness ratio
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